PSYCHIATRIE PRO PRAXI / Psychiatr. praxi. 2025;26(1):55-62 / www.psychiatriepropraxi.cz 62 ZAZNĚLO NA KONGRESE Farmakoterapie schizofrenie při komorbidním abúzu. Využití kariprazinu v klinické praxi Závěr Kariprazin má příznivý vliv na celkové příznaky schizofrenie prokázaný jak v klinických studiích, tak pozorovaný v reálné praxi. Významně zlepšuje psychosociální fungování pacienta, a umožňuje tak návrat k běžnému fungování. Recentní studie poukazují i na příznivý účinek kariprazinu na zmírnění četnosti užívání návykových látek. Vhodně zvolená kombinace antipsychotik může vést k potenciaci efektu léčby a zmírnění nežádoucích účinků (např. metabolických). Kariprazin je nově k dispozici i v rozpustné formě ve všech lékových silách. LITERATURA 1. Khokhar JY, Dwiel LL, Henricks AM, et al. The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophr Res. 2018 Apr;194:78-85. 2. Alsuhaibani R, Smith DC, Lowrie R, et al. Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review. BMC Psychiatry. 2021 Apr 23;21(1):209. 3. Hernández-Huerta D, Morillo-González J. Dopamine D3 partial agonists in the treatment of psychosis and substance use disorder comorbidity: a pharmacological alternative to consider? CNS Spectr. 2021 Oct;26(5):444-445. 4. Ward HB, et al. Substance use disorders in schizophrenia: Prevalence, etiology, biomarkers, and treatment. Pers. Med. July–August 2023;39-40:100106. 5. Nathan R, Lewis E. Assessment of coexisting psychosis and substance misuse: complexities, challenges and causality. BJPsych Advances. Jan 2021;(1)27:38-48. 6. Souza DC, DiForti M, Ganesh S, et al. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. World J Biol Psychiatry. 2022 Dec;23(10):719-742. 7. Alsuhaibani R, Smith DC, Lowrie R, et al. Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review. BMC Psychiatry. 2021 Apr 23;21(1):209. 8. Starzer MSK, Hansen HG, Hjorthøj C, et al. Predictors of Mortality Following a Schizophrenia Spectrum Diagnosis: Evidence From the 20-Year Follow-up of the OPUS Randomized Controlled Trial. Schizophr Bull. 2023 Sep 7;49(5):1256-1268. 9. Thoma P, Daum I. Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. Psychiatry Clin Neurosci. 2013 Sep; 67(6):367-383. 10. Kendler KS, Ohlsson H, Sundquist J, Sundquist K. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample. Am J Psychiatry. 2019 Sep 1;176(9):711-719. 11. Starzer MSK, Nordentoft M, Hjorthøj C. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. Am J Psychiatry. 2018 Apr 1;175(4):343-350. 12. Levi L, Bar-Haim M, Winter-van Rossum I, et al. Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study. Schizophr Bull. 2023 Jul 4; 49(4):903-913. 13. Schoeler T, Petros N, Di Forti M, et al. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry. 2016 Oct;3(10):947-953. 14. Agid, et al. Neuropsychopharmacology. 2014;39:S373–S374 15. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge: Cambridge University Press; 2021. 16. Boileau I, Payer D, Houle S, et al. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci. 2012 Jan 25;32(4):1353-1359. 17. Zhan J, Jordan CJ, Bi GH, et al. Genetic deletion of the dopamine D3 receptor increases vulnerability to heroin in mice. Neuropharmacology. 2018 Oct;141:11-20. 18. Martinotti G, Chiappini S, Mosca A, et al. Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice. Curr Pharm Des. 2022;28(27):2241-2259. 19. Galaj E, Newman AH, Xi ZX. Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges. Neurosci Biobehav Rev. 2020 Jul;114:38-52. 20. Grunze H. The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder. Expert Opin Pharmacother. 2023 Sep-Dec;24(18):1985-1992. 21. Machielsen M, Beduin AS, Dekker N, et al; Genetic Risk and Outcome of Psychosis (GROUP) investigators. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol. 2012 Jan;26(1):189-195. 22. Martinotti G, Chiappini S, Mosca A, et al. Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice. Curr Pharm Des. 2022;28(27):2241-2259. 23. Martinez-Raga J, Bajouco M, Kenzin D, et al. Dual disorder: does expert clinical experience support the rationale for cariprazine use? Eur Rev Med Pharmacol Sci. 2024 Mar; 28(5):2095-2106. 24. Masopust J, Mohr P, Kopeček M. Antipsychotika v léčbě predominantních negativních příznaků schizofrenie: aktualizace doporučených postupů. Psychiatrie. 2020; 24(1):40–45. 25. Szerman N, Vega P, Roncero C, et al. Cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder. Int Clin Psychopharmacol. 2024 Sep 25. 26. Phahladira L, Luckhoff HK, Asmal L, et al. Early recovery in the first 24 months of treatment in first-episode schizophrenia-spectrum disorders. NPJ Schizophr. 2020 Jan 8;6(1):2.
RkJQdWJsaXNoZXIy NDA4Mjc=